Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive ...

They offer investors very different value propositions.

Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...

DexCom (DXCM) closed the latest trading day at $134.56, indicating a -1.16% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 1.2%. Meanwhile, the ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...

Progress in medicine could lead to a smaller target market for DexCom. However, the company is expanding opportunities through innovation. On the other hand, DexCom has attractive opportunities that ...